Document Detail


Low-molecular-weight heparin during pregnancy.
MedLine Citation:
PMID:  11342097     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thromboembolism is an infrequent, yet serious cause of both maternal and fetal morbidity and death during pregnancy and the puerperium. Pregnancy itself increases the risk of thromboembolic complications probably owing to a combination of hypercoagulability and venous stasis due to venous dilation. Recent studies have indicated that some serious obstetric complications are correlated with inherited or acquired thrombophilia. The prevalence of venous thromboembolism (VTE) has been extimated to be 1 per 1000-2000 pregnancies in retrospective studies. Anticoagulant treatment and prophylaxis both before and during pregnancy are based on unfractionated heparin (UH), low-molecular-weight heparin (LMWH) and warfarin. Warfarin is teratogenous if administered between the 6th and the 12th week. LMWH is replacing UH in the prevention and treatment of VTE both outside and more recently during pregnancy with the same indications, and also for obstetric complications. This paper assesses the safety and efficacy of heparin therapy during pregnancy and the puerperium. Its cardiovascular and obstetric indications and regimens and maternal and fetal side-effects are also discussed.
Authors:
M Bazzan; V Donvito
Related Documents :
14712967 - Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and mon...
9732087 - Recurrent miscarriage: causes, evaluation, and treatment.
3766627 - Use of the greenfield filter for thromboembolic disease in pregnancy.
10647757 - Anticoagulation of pregnant women with mechanical heart valves: a systematic review of ...
21401637 - Placental hofbauer cells and complications of pregnancy.
8648457 - Racial disparity in pregnancy outcomes: analysis of black and white teenage pregnancies.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Thrombosis research     Volume:  101     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-05-08     Completed Date:  2001-07-12     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  V175-86     Citation Subset:  IM    
Affiliation:
Servizio di Ematologia e Malattie Trombotiche, Ospedale Evangelico Valdese, Torino, Italy
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Heparin, Low-Molecular-Weight / administration & dosage*,  standards
Humans
Pregnancy
Pregnancy Complications, Hematologic / drug therapy,  prevention & control*
Risk Factors
Thromboembolism / drug therapy,  epidemiology,  prevention & control
Venous Thrombosis / drug therapy,  epidemiology,  prevention & control
Chemical
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous throm...
Next Document:  Positive and negative regulation of squalene synthase (ERG9), an ergosterol biosynthetic gene, in Sa...